myCare-021-02 study discovers patient-specific resistance mechanisms that can inform treatment planning and improve AML patient outcomes myCare-021-02 study discovers patient-specific resistance mechanisms that can inform treatment planning and improve AML patient outcomes

Read the rest here:
Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

myCare-021-04 study finds genetic signatures associated with 100% remission rate fromAML induction therapy despite presence of Monosomy 7

Read the original here:
Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7

AUTO3 continues to show a differentiated product profile supporting outpatient administration

More here:
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting

myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and sensitivity in predicting complete response to physician prescribed therapies for AML and MDS patients myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and sensitivity in predicting complete response to physician prescribed therapies for AML and MDS patients

See the original post here:
Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients

myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders

Originally posted here:
Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

Daix (France), December 7, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the publication of a scientific paper on the beneficial effects of lanifibranor on experimental advanced chronic liver disease (ACLD) by the peer-reviewed scientific journal Journal of Hepatology.

Read the original post:
Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis

Original post:
Signal Relief Patch Reviews – Pain Patch launched - Product Review by Mike Vaughn

SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A. Collard, a seasoned biopharmaceutical leader with over 20 years of commercial and executive experience, to Chairman of its Board of Directors, effective January 1, 2021. Mr. Collard joined the Opiant board in 2018. Gabrielle Silver, M.D., who has served as Lead Independent Director since October, 2018, will remain an independent director on the Board and continue to be Chairman of the Nominating and Governance Committee.

Visit link:
Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020, and provides guidance for 2021.

Originally posted here:
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a clinical update for its three most advanced TriTAC® programs. The discussion will be focused on HPN424 for the treatment of metastatic castration resistant prostate cancer, HPN536 initially in development for ovarian and pancreatic cancer and mesothelioma, and HPN217 for relapsed/refractory multiple myeloma.

The rest is here:
Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will provide an end-of-year business update on veverimer’s development program, regulatory status and patent protection.

View original post here:
Tricida to Provide an End-of-Year Business Update

BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET.

Read more here:
Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020

TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Jeanne Thoma as an independent member of the company’s board of directors. Ms. Thoma is a seasoned pharmaceutical industry executive with more than 30 years of experience spanning product development and commercialization, as well as operations and supply chain management.

Read more:
Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors

– Treatment with Mitapivat Induced Hemoglobin Increase of ?1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients, Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –

Originally posted here:
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/.

See more here:
Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference

BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference.

Read the original here:
electroCore to Present at the 13th Annual LD Micro Main Event Conference

Unique Product Development Model Delivers Accelerated Growth

Visit link:
Syneos Health to Outline Value Creation Plan at 2020 Analyst and Investor Event

Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT)

Continue reading here:
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

Link:
Roche presents new data from its bispecific antibody portfolio across a range of blood cancers

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, and Alnylam Pharmaceuticals, Inc. (“Alnylam”), the leading RNAi therapeutics company, announced today the launch of a new joint clinical screening program: the genetic screening of the at-risk population for hereditary TransthyRetin-related AMyloidosis and longitudinal monitoring of TTR positive subjects (the “TRAMmoniTTR Study”).

Read the original post:
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related...